Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success
First Progress In Frontline DLBCL In 20 Years
Executive Summary
Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.
You may also be interested in...
Roche’s Polivy Wins US Approval In Untreated Lymphoma But Blockbuster Potential Uncertain
The firm’s antibody-drug conjugate plus Rituxan and R-CHP chemoimmunotherapy has won a US thumbs up for first-line diffuse large B-cell lymphoma but lingering concerns about magnitude of benefit could lead to limited uptake.
Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth
Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.
New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.